Compare AbbVie Inc (ABBV) vs Apollo Global Management Ord Shs (APO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Apollo Global Management Ord Shs — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while Apollo Global Management Ord Shs trades at $118.29 (market cap $68.80B). The key difference: AbbVie Inc is far larger — about 6.5× Apollo Global Management Ord Shs's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | APO | |
|---|---|---|
Market Cap | $449.91B | $68.80B |
Sector | Health | Financials |
52-Week High | $261.07 | $156.05 |
52-Week Low | $184.85 | $100.30 |
Enterprise Value | $513.38B | -$168.77B |
Dividend Yield | 2.72% | 1.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
Apollo Global Management (APO) trades at $119.33, up 0.61% with a bearish technical signal despite strong analyst consensus. The company reported Q1 2026 EPS of $1.94, beating expectations, and maintains a 95.15% gross margin. Recent news highlights liquidity pressures in private credit funds, with Apollo capping withdrawals from its $25 billion Apollo Debt Solutions fund after 17% redemption requests in Q2 2026.
Outlook remains mixed: strong fee-generating AUM growth and dividend increases support bullish analyst targets averaging $149.71, but near-term risks include private credit liquidity concerns and multiple law firm investigations. The stock offers 25% upside to consensus target if liquidity pressures ease and earnings meet guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Apollo Global Management Ord Shs
Apollo Global Management Inc is an alternative investment manager. It serves various sectors such as chemicals, manufacturing and industrial, natural resources, consumer and retail, consumer services, business services, financial services, leisure, and media and telecom and technology. The company operates in three business segments that are Private Equity, Credit, and Real Assets. It generates maximum revenue from the Credit segment in the form of fees. The credit segment primarily invests in non-control corporate and structured debt instruments including performing, stressed and distressed instruments across the capital structure. It also includes Corporate Credit
Read more on APO →
